Clinical Trial Update: Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects [Phase 3]

View source ↗

Summary

Phase 3 method-of-use study completed to assess the effect of sustained-release naltrexone/bupropion on body weight and cardiovascular risk factors in overweigh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Contrave (naltrexone SR / bupropion SR) (naltrexone; bupropion)

Snippet

Sponsor: Orexigen Therapeutics, Inc | Conditions: Obesity, Overweight | Phase 3 | Status: COMPLETED | Results posted: 2015-11-26